287 related articles for article (PubMed ID: 29845347)
1. Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma.
Wehrenberg-Klee E; Goyal L; Dugan M; Zhu AX; Ganguli S
Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1799-1802. PubMed ID: 29845347
[TBL] [Abstract][Full Text] [Related]
2. Yttrium-90 Radioembolization for Hepatocellular Carcinoma.
Hickey RM; Lewandowski RJ; Salem R
Semin Nucl Med; 2016 Mar; 46(2):105-8. PubMed ID: 26897714
[TBL] [Abstract][Full Text] [Related]
3. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
Wang EA; Stein JP; Bellavia RJ; Broadwell SR
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
[TBL] [Abstract][Full Text] [Related]
4. Imaging of Hepatocellular Carcinoma Response After
Semaan S; Makkar J; Lewis S; Chatterji M; Kim E; Taouli B
AJR Am J Roentgenol; 2017 Nov; 209(5):W263-W276. PubMed ID: 29072955
[TBL] [Abstract][Full Text] [Related]
5. Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma.
Zhan C; Ruohoniemi D; Shanbhogue KP; Wei J; Welling TH; Gu P; Park JS; Dagher NN; Taslakian B; Hickey RM
J Vasc Interv Radiol; 2020 Jan; 31(1):25-34. PubMed ID: 31422022
[TBL] [Abstract][Full Text] [Related]
6. Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience.
Tohme S; Sukato D; Chen HW; Amesur N; Zajko AB; Humar A; Geller DA; Marsh JW; Tsung A
J Vasc Interv Radiol; 2013 Nov; 24(11):1632-8. PubMed ID: 24160821
[TBL] [Abstract][Full Text] [Related]
7. Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: a single centre experience of 45 consecutive patients.
Saxena A; Meteling B; Kapoor J; Golani S; Danta M; Morris DL; Bester L
Int J Surg; 2014 Dec; 12(12):1403-8. PubMed ID: 25091398
[TBL] [Abstract][Full Text] [Related]
8. Superselective yttrium-90 radioembolization for hepatocellular carcinoma in high-risk cases: another tool in the toolbox.
Brown KT
J Vasc Interv Radiol; 2014 Jul; 25(7):1073-4. PubMed ID: 24968727
[No Abstract] [Full Text] [Related]
9. Combining systemic and local therapies for hepatocellular carcinoma.
Wehrenberg-Klee E; Goyal L
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):976-978. PubMed ID: 34695376
[No Abstract] [Full Text] [Related]
10. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial.
Tai D; Loke K; Gogna A; Kaya NA; Tan SH; Hennedige T; Ng D; Irani F; Lee J; Lim JQ; Too CW; Ng MCH; Tham CK; Lam J; Koo SL; Chong HS; Goh GB; Huang HL; Venkatanarasimha N; Lo R; Chow PKH; Goh BKP; Chung A; Toh HC; Thng CH; Lim TKH; Yeong J; Zhai W; Chan CY; Choo SP
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1025-1035. PubMed ID: 34695377
[TBL] [Abstract][Full Text] [Related]
11. Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.
Ricke J; Bulla K; Kolligs F; Peck-Radosavljevic M; Reimer P; Sangro B; Schott E; Schütte K; Verslype C; Walecki J; Malfertheiner P;
Liver Int; 2015 Feb; 35(2):620-6. PubMed ID: 24930619
[TBL] [Abstract][Full Text] [Related]
12. Comments on "Hepatic radioembolization with yttrium-90 glass microspheres for treatment of primary liver cancer" by Cao et al, Chin Med J 1999; 112: 430-432.
Ho S; Lau WY; Leung WT
Chin Med J (Engl); 2001 Apr; 114(4):433-4. PubMed ID: 11780473
[No Abstract] [Full Text] [Related]
13. Transarterial chemoembolization and yittrium-90 for liver cancer and other lesions.
Minocha J; Salem R; Lewandowski RJ
Clin Liver Dis; 2014 Nov; 18(4):877-90. PubMed ID: 25438288
[TBL] [Abstract][Full Text] [Related]
14. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival.
Hilgard P; Hamami M; Fouly AE; Scherag A; Müller S; Ertle J; Heusner T; Cicinnati VR; Paul A; Bockisch A; Gerken G; Antoch G
Hepatology; 2010 Nov; 52(5):1741-9. PubMed ID: 21038413
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of radioembolization in identifying patients with favorable tumor biology before living donor liver transplantation.
Yu YD; Kim DS; Jung SW; Kim Y; Suh SO
Transplantation; 2014 Sep; 98(5):e47-50. PubMed ID: 25171535
[No Abstract] [Full Text] [Related]
16. Downstaging Hepatocellular Carcinoma with Yttrium-90 radioembolization: resection or transplantation?
Ettorre GM; Laurenzi A; Vennarecci G
Eur J Surg Oncol; 2014 Jun; 40(6):789-90. PubMed ID: 24572481
[TBL] [Abstract][Full Text] [Related]
17. Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging.
Rhee TK; Naik NK; Deng J; Atassi B; Mulcahy MF; Kulik LM; Ryu RK; Miller FH; Larson AC; Salem R; Omary RA
J Vasc Interv Radiol; 2008 Aug; 19(8):1180-6. PubMed ID: 18656011
[TBL] [Abstract][Full Text] [Related]
18. Transarterial radioembolization with Yttrium-90 for regional management of hepatocellular cancer: the early results of a nontransplant center.
Holt A; Wagman LD; Senthil M; McKenzie S; Marx H; Chen YJ; Vora N; Kim J
Am Surg; 2010 Oct; 76(10):1079-83. PubMed ID: 21105614
[TBL] [Abstract][Full Text] [Related]
19. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [Abstract][Full Text] [Related]
20. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity.
Padia SA; Kwan SW; Roudsari B; Monsky WL; Coveler A; Harris WP
J Vasc Interv Radiol; 2014 Jul; 25(7):1067-73. PubMed ID: 24837982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
